MedTrace Logo

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

NCT06457919 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-24

No results posted yet for this study

Summary

The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Interventions

DRUG

Tinengotinib

Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.

DRUG

abiraterone acetate with prednisone

Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)

DRUG

Enzalutamide

Enzalutamide 160 mg PO QD

Sponsors & Collaborators

Principal Investigators

  • Wassim Abida, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-04
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06457919 on ClinicalTrials.gov